Abstract: The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is hydrogen; loweralkyl; arylalkyl; Or.sub.10 wherein R.sub.10 is hydrogen or loweralkyl; NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently selected from hydrogen and loweralkyl; or R.sub.13 --CO--B wherein B is NH, O, CH.sub.2, HNCH.sub.2 and R.sub.13 is loweralkyl, alkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, aminoalkyl, N-protected aminoalkyl, hydroxylated dialkylamino, (heterocyclic)alkyl or a substituted or unsubstituted heterocyclic, carboxyalkyl, or lower alkyl carboxyalkyl esters; W is N or CH: U,V may be the following combinations H,OH; OH,H; H,H; or when taken together as O represents a carbonyl with the provisos that if U,V.dbd.H,OH, then W=CH, and if U,V.dbd.O then W.dbd.N; R.sub.1 , R.sub.3 and R.sub.5 are loweralkyl or hydrophilic, lipophilic or aromatic amino acid side chains and may be the same or different; R.sub.2, R.sub.4, R.sub.7, R.sub.8 and R.sub.

Abstract: Vasopressin antagonists which have a 4'-methyl-.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid group have vasopressin antagonist activity without substantial agonist activity. A species of the invention is [1-(4'-methyl-.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)-2-(O-ethyl)-D-tyrosine-4-valine-8-arginine]vasopressin.

Abstract: There are provided tripeptide compounds represented by the following formula ##STR1## wherein R.sub.1 represents a C.sub.1-10 alkyl group, a C.sub.4-7 cycloalkyl or C.sub.

Abstract: A method for the production of N-carbobenzoxy-.alpha.-L-aspartyl-L-phenylalanine methyl ester characterized by the reaction of L-phenylalanine methyl ester with fine N-carbobenzoxy-L-aspartic anhydride crystals, is disclosed.

Abstract: Novel peptides having immunosuppressive or immunoregulatory activity are disclosed.

Abstract: A peptide is novel and useful for the bronchodilative activity and the hypotensive activity, having the following structure:His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-X-Ala-Val-L ys -Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-Gly-Y(wherein X is Met or Leu; and Y is OH, Lys-OH, Arg-OH, Lys-Arg-OH, or Lys-NH.sub.2 when X is Met, or Y is Lys-NH.sub.2, Lys-OH, or Lys-Arg-OH when X is Leu).

Abstract: A mediator substance exhibiting inhibitory effect upon anabolic enzyme activity in mammals, is prepared by a method comprising gathering a sample of macrophage cells from a mammal, incubating a portion of the macrophage cells with a stimulating mateThis invention was made in the course of a grant from the National Institutes of Health.

Abstract: New bicyclic compounds, inclusive of salts thereof, of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each represents hydrogen, hydroxyl or lower alkoxy, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is hydrogen, lower alkyl, amino-lower-alkyl or acylamino-lower-alkyl, R.sup.5 is hydrogen, lower alkyl or aralkyl which may be substituted, R.sup.6 is hydroxyl, lower alkoxy, amino or lower alkylamino, and m and n each means 1 or 2, have inhibitory activities of angiotensin converting enzyme and bradykinin decomposing enzyme, and are useful as antihypertensive agents.

Abstract: New hypocalcaemic peptides are disclosed of the formula ##STR1## wherein X represents H for the replacement of the N alpha amino group or acyl groups for the acylation of the N alpha amino group, the N-alpha amino group. The acyl groups are carboxylic acids especially formic, acetic, propionic, buteric, valeric, hexanoic, heptanoic, octanoic, and nonanoic acids or their respective isomers, L-lactic acid and the half amides of malonic, succinic, glutaric and adipic acids. Y is L-valine, glycine, L-methionine, L-alanine, L-leucine or L-isoleucine.

Abstract: Compounds of the formula ##STR1## wherein R and R.sub.9 are independently hydroxy or lower alkoxy,R.sub.1 and R.sub.2 are hydrogen or lower alkyl, aryl-lower alkyl having from 7 to 12 carbon atoms, or heterocyclic-lower alkyl having from 6 to 12 carbon atoms,R.sub.3, R.sub.4, R.sub.5, R.sub.7 and R.sub.8 are hygrogen or lower alkyl,R.sub.6 is cycloalkly having from 3 to 20 carbon atoms, aryl or aryl-lower alkyl, and the aryl group contains from 6 to 10 carbon atoms, and their pharmaceutically acceptable, nontoxic acid addition salts and where R or R.sub.9 or both are hydroxy, their pharmaceutically acceptable, nontoxic basic salts possess antihypertensive activity.

Abstract: Compounds of the formula ##STR1## are disclosed. These compounds interevene in the conversion of angiotensin to angiotensin II by inhibiting renin and thus are useful as anti-hypertensive agents.

Abstract: Anti-hypertensive compounds of the formula ##STR1## in which A represents hydrogen, C.sub.1 -C.sub.8 -alkyl, C.sub.7 -C.sub.14 -aralkyl, phenylsulphonyl, tolylsulphonyl or C.sub.1 -C.sub.8 -alkylsulfphonyl, or represents an aminoprotective group,B represents a direct bond, or represents sarcosyl, or represents a group of the formula ##STR2## D represents a direct bond, or represents a group of the formula ##STR3## wherein X represents methylene, ethylene or sulphur,E, G, J, K, L and M independently have the same meanings as B,R.sup.1 is an optionally substituted phenyl radical, andQ is a hydroxy, alkoxy or amino group, or a physiologically acceptable salt thereof.

Abstract: Human growth hormone is used for the treatment of individuals who are intoxicated with poisonous substances of the type which is degraded in the liver by microsomal enzymes, such as hexobarbiturates or alcohol.

Abstract: Growth hormones are admixed with various stabilizers to provide for the decreased formation of insolubles and preservation of the soluble bioactivity of the growth hormone in aqueous environments. Examples of such stabilizers include certain polyols, amino acids, polymers of amino acids having a charged side group at physiological PH, and choline salts.

Abstract: Peptides of the formula R.sup.1 -His-Asp-Glu-Ala-R wherein R.sup.1 is Ala-Gln, and R is a polypeptide residue with up to 50 amino acid residues, and wherein one, more or all of the amino acid residues in R.sup.1 and/or R independently may be omitted, can be used to augment cell mediated cytotoxicity and thereby to treat cancers and viral infections. These peptides may be prepared by proteolytic digestion of Staphylococcus aureus protein A, as well as by protein synthesis, recombinant DNA methods or any other methods known in the art.

Abstract: Novel compounds represented by the following general formula (1) and salts thereof: ##STR1## wherein n represents an integer of 3 to 4, R.sup.1 represents ##STR2## or --SO.sub.2 R.sup.2, and R.sup.2 represents optionally branched lower alkyl group having 1 to 6 carbon atoms, phenyl group, benzyl group or tolyl group, which are useful as substrate for use in the measurement of biological components; a substrate for use in the measurement of biological component which comprises said novel compound or salt thereof; and a method for measuring biological component which comprises using said substrate.

Abstract: Novel peptides having potent natriuretic activity are disclosed with the following amino acid sequence: ##STR1## wherein Z is H, acetyl, Boc or Ser-Leu, E is Phe, NMP, OMT, ChA, F is Gly or DAl, G is Ala or Gly, H is Arg or DAr, Pro, Lys or Dly, I is Ile, Met, MeO, MO.sub.2, Leu, Nle, or Val, J is Aib, .alpha.MG or .alpha.MA, K is Arg or Lys, L is Ile or Val, M is Aib, Gly, Ala or DAl, N is Ala, NMA, Pro, Phe or NMP, O is Gln, DGl, Ala or DAl, P is Ser, His, Arg or Lys, Q is Gly, Pro, Ala or Dal, R is Leu, Phe or ChA, S is Gly, Ala or Dal, Arg or DAr, T is Asn DAs, Ala or Dal, U is Ser, DSe, Ala or DAl, V is Phe, DPh, Ala or DAl, Y is -OH or -NH.sub.2 and n is 0 or 1. Also included are the lower alkyl esters and the physiologically acceptable metal salts and acid addition salts of the foregoing peptides. Unless indicated otherwise all optically active amino acids have the L-configuration.

Abstract: Novel biologically active polypeptides, including a new class of transforming growth factor (TGF) polypeptides, which exhibit cell growth promoting properties are disclosed, as well as a process for isolating the TGF polypeptides from both human and murine cell lines in homogeneous form. Also disclosed are antigenic oligopeptides derived from the TGF polypeptides and antibodies raised therefrom which have application in the detection and treatment of malignancies and oligipeptides which have the ability to bind with cellular growth factor receptors and thus to interfere with transformation of certain cell lines into a cancerous state. Compositions and methods based on the disclosed peptides for detection and treatment of cancer and other proliferative diseases and for cell or tissue growth associated treatment, e.g., wound healing, ulcer therapy and bone loss are also described.

Abstract: The iron-containing biologically active peptide TAN-866 produced by microorganisms belonging to the genus Pseudomonas and its iron free compounds have antibacterial activity mainly against gram-negative bacteria. These peptides can be used as a therepeutic agent for bacterial infections in mammals, domestic fowl, etc., caused by Pseudomonas aeruginosa. Further, TAN-866 and its deacyl compounds are also promising as the starting materials and intermediates for the synthesis of novel products.

Abstract: New partially retro-inverted tuftsin analogues of general formula I ##STR1## wherein R represents the side-chain of the amino acids threonine, methionine or leucineR.sup.1 represents the side-chain of the amino acids lysine or arginineR.sup.2 is hydrogen or a metabolically labile acyl group,all the asymmetric carbon atoms are either of the S- or R-configuration, or, alternatively, the first, third, and fourth asymmetric carbons, starting from the N-terminal residue, are of the S-configuration while the second one is of the R- or (R,S)-configuration, and the corresponding pharmacologically acceptable salts, esters and amides. The new compounds which share the same pharmacological properties of tuftsin, are much more stable toward the enzymatic degradation than the parent molecule.